Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Connect Biopharma Holdings ( (CNTB) ) just unveiled an update.
On July 9, 2025, Connect Biopharma announced that its collaborator, Simcere Pharmaceutical, submitted a New Drug Application for rademikibart to China’s National Medical Products Administration for treating atopic dermatitis in adults and adolescents. This submission marks a significant step in advancing rademikibart in China, potentially impacting the large atopic dermatitis market, which comprises an estimated 70 million patients. The collaboration with Simcere, which began in 2023, grants Simcere exclusive rights to develop and commercialize rademikibart in Greater China, while Connect retains rights elsewhere, with potential milestone payments and royalties from sales in China.
The most recent analyst rating on (CNTB) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Connect Biopharma Holdings stock, see the CNTB Stock Forecast page.
Spark’s Take on CNTB Stock
According to Spark, TipRanks’ AI Analyst, CNTB is a Neutral.
Connect Biopharma Holdings’ overall score reflects the challenges of unprofitability and negative cash flow despite recent revenue growth and a strong balance sheet. Technical indicators suggest a bearish trend, while the valuation highlights the risks typical of early-stage biotech firms. However, the positive corporate event regarding FDA support for Phase 2 trials offers a promising growth opportunity in the pipeline, improving the outlook.
To see Spark’s full report on CNTB stock, click here.
More about Connect Biopharma Holdings
Connect Biopharma Holdings Limited is a global, clinical-stage biopharmaceutical company focused on developing innovative therapies for inflammatory diseases. Their lead product candidate, rademikibart, is an antibody targeting IL-4Rα, with demonstrated activity in atopic dermatitis and asthma. The company is conducting global studies on rademikibart for asthma and COPD, addressing significant unmet needs.
Average Trading Volume: 130,269
Technical Sentiment Signal: Hold
Current Market Cap: $63.1M
Learn more about CNTB stock on TipRanks’ Stock Analysis page.